Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | YAP1 | P46937 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697006 | 1.00 | KDM1A (0.48) | KDM1AMAOAMAOBCYP4F2CYP4A11 | |
| SCHEMBL8337436 | 0.87 | EPHX2 (0.49) | EPHX2EPHX1 | |
| SCHEMBL6701117 | 0.87 | EPHX2 (0.49) | EPHX2EPHX1 | |
| SCHEMBL6701112 | 0.87 | EPHX2 (0.49) | EPHX2EPHX1 | |
| Hydrochloric Acid SCHEMBL5961236 | 0.86 | EPHX2 (0.48) | EPHX2EPHX1 | |
| Hydrochloric Acid SCHEMBL5961238 | 0.86 | EPHX2 (0.48) | EPHX2EPHX1 | |
| SCHEMBL20754970 | 0.81 | L3MBTL1 (0.54) | MAOAMAOBP4HTM | |
| SCHEMBL6716983 | 0.79 | KMT2A (0.46) | KDM1AMAOAMAOBP4HTM | |
| SCHEMBL6716995 | 0.79 | KMT2A (0.46) | KDM1AMAOAMAOBP4HTM | |
| SCHEMBL6700517 | 0.79 | FFAR1 (0.44) | CYP4F2CYP4A11FFAR4FFAR1P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | KAWAI MAKOTO (JP) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | GRIN1, GRIN3A, GRIN2A | KDM1A 855/4885MAOA 2028/4885MAOB 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.